000308510 001__ 308510
000308510 005__ 20260120150414.0
000308510 0247_ $$2doi$$a10.1093/ejendo/lvag010
000308510 0247_ $$2pmid$$apmid:41554104
000308510 0247_ $$2ISSN$$a0001-5598
000308510 0247_ $$2ISSN$$a0804-4643
000308510 0247_ $$2ISSN$$a1479-683X
000308510 0247_ $$2ISSN$$a2053-4167
000308510 037__ $$aDKFZ-2026-00150
000308510 041__ $$aEnglish
000308510 082__ $$a610
000308510 1001_ $$00000-0002-2348-1105$$aTrocchi, Pietro$$b0
000308510 245__ $$aEndocrine and metabolic late-effects in childhood cancer survivors in Germany: the VersKiK-Study.
000308510 260__ $$aOxford$$bOxford University Press$$c2026
000308510 3367_ $$2DRIVER$$aarticle
000308510 3367_ $$2DataCite$$aOutput Types/Journal article
000308510 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1768917841_2404008
000308510 3367_ $$2BibTeX$$aARTICLE
000308510 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000308510 3367_ $$00$$2EndNote$$aJournal Article
000308510 500__ $$aepub
000308510 520__ $$aEndocrine and metabolic diseases are known to be common late effects in childhood cancer survivors (CCS). We assessed the prevalence of these diseases in a large German CCS cohort, and a matched comparison population, using health claims data.The cohort study was based on record-linkage between the nationwide German Childhood Cancer Registry and claims data from 13 major German statutory health insurances.The monitored insurance period covered the years 2017-2021. We assessed the frequencies of endocrine and metabolic diseases among 11 863 5-year CCS, diagnosed 1991-2021, with continuous insurance coverage and a matched comparison group of 35 589 insured persons without a history of childhood cancer. We present prevalence and Prevalence Ratios (PR) with corresponding 95% confidence intervals (95%CI).At least one endocrine or metabolic disease was recorded in 31.3% of survivors (n=3716) and in 16.4% of the comparison group (n=5819, PR=1.9; 95%CI: 1.8-2.0). The frequency of diseases was higher among females than among males in both groups. The PR was 2.4 (95%CI: 2.3-2.5) for males and 1.6 (95%CI: 1.5-1.7) for females. The frequency of at least one disease increased with increasing attained age. The disease with the highest frequency among CCS was hypothyroidism (15.85%), the highest PR was estimated for patients with primary thyroid cancer (43.5; 95%CI: 24.2-78.1).Our study highlights the increased vulnerability of CCS to endocrine and metabolic diseases compared to the general population and underscores the need for risk-adapted surveillance during the whole survivorship trajectory.
000308510 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000308510 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000308510 650_7 $$2Other$$acancer registry
000308510 650_7 $$2Other$$acancer survivorship
000308510 650_7 $$2Other$$achildhood cancer
000308510 650_7 $$2Other$$aclaims data
000308510 650_7 $$2Other$$afollow-up care
000308510 650_7 $$2Other$$alate effects
000308510 7001_ $$aSwart, Enno$$b1
000308510 7001_ $$aAleshchenko, Ekaterina$$b2
000308510 7001_ $$aMerzenich, Hiltrud$$b3
000308510 7001_ $$0P:(DE-He78)179d42bde859e38f13bb914c552cc4e5$$aRonckers, Cecile$$b4$$udkfz
000308510 7001_ $$aBaust, Katja$$b5
000308510 7001_ $$00000-0002-7893-7982$$aCalaminus, Gabriele$$b6
000308510 7001_ $$00000-0002-7047-2957$$aLanger, Thorsten$$b7
000308510 7001_ $$aIhle, Peter$$b8
000308510 7001_ $$aKuepper-Nybelen, Jutta$$b9
000308510 7001_ $$aLuepkes, Christian$$b10
000308510 7001_ $$aDroege, Patrik$$b11
000308510 7001_ $$00000-0002-5955-4142$$aRuhnke, Thomas$$b12
000308510 7001_ $$aHorenkamp-Sonntag, Dirk$$b13
000308510 7001_ $$aMarschall, Ursula$$b14
000308510 7001_ $$aKlein, Melanie$$b15
000308510 7001_ $$00000-0002-2123-9315$$aSpix, Claudia$$b16
000308510 7001_ $$00000-0003-3805-8219$$aApfelbacher, Christian$$b17
000308510 7001_ $$aGebauer, Judith$$b18
000308510 773__ $$0PERI:(DE-600)1485160-X$$a10.1093/ejendo/lvag010$$gp. lvag010$$pnn$$tEuropean journal of endocrinology$$vnn$$x0001-5598$$y2026
000308510 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)179d42bde859e38f13bb914c552cc4e5$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000308510 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000308510 9141_ $$y2026
000308510 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-20
000308510 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-20
000308510 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J ENDOCRINOL : 2022$$d2024-12-20
000308510 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-20
000308510 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-20
000308510 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-20
000308510 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-20
000308510 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-20
000308510 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-20
000308510 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-20
000308510 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-20
000308510 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-20
000308510 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-20
000308510 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J ENDOCRINOL : 2022$$d2024-12-20
000308510 9201_ $$0I:(DE-He78)C190-20160331$$kC190$$lCAYA Cancer Survivorship Forschung$$x0
000308510 980__ $$ajournal
000308510 980__ $$aVDB
000308510 980__ $$aI:(DE-He78)C190-20160331
000308510 980__ $$aUNRESTRICTED